IRELLI, AZZURRA
 Distribuzione geografica
Continente #
NA - Nord America 376
EU - Europa 295
AS - Asia 78
SA - Sud America 3
OC - Oceania 1
Totale 753
Nazione #
US - Stati Uniti d'America 374
IE - Irlanda 105
IT - Italia 54
DE - Germania 49
CN - Cina 40
SE - Svezia 34
TR - Turchia 23
UA - Ucraina 14
CZ - Repubblica Ceca 10
GB - Regno Unito 10
FI - Finlandia 7
VN - Vietnam 7
IN - India 6
FR - Francia 4
BR - Brasile 2
CA - Canada 2
BE - Belgio 1
BG - Bulgaria 1
EE - Estonia 1
ES - Italia 1
HR - Croazia 1
HU - Ungheria 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PE - Perù 1
RO - Romania 1
SG - Singapore 1
TH - Thailandia 1
Totale 753
Città #
Chandler 102
Dublin 101
Jacksonville 66
Boardman 23
Izmir 13
L'aquila 13
Princeton 13
Ashburn 12
Berlin 12
Bremen 12
Lawrence 12
New York 12
Brno 10
Nanjing 10
San Mateo 9
Dong Ket 6
Munich 6
Wilmington 6
Civitanova Marche 5
Des Moines 5
Shenyang 5
Beijing 4
Norwalk 4
Woodbridge 4
Hebei 3
Los Angeles 3
Milan 3
Pune 3
Redwood City 3
Aquila 2
Dearborn 2
Helsinki 2
Kitzingen 2
Mountain View 2
Rome 2
San Francisco 2
Taizhou 2
Tianjin 2
Verona 2
Ann Arbor 1
Arzignano 1
Bangkok 1
Brussels 1
Budapest 1
Cambridge 1
Cologne 1
Fairfield 1
Frankfurt am Main 1
Fremont 1
Grafing 1
Hanoi 1
Hefei 1
Istanbul 1
Kunming 1
Lanciano 1
Lappeenranta 1
Lima 1
Madrid 1
Montesilvano Marina 1
Motueka 1
Nanchang 1
Nuremberg 1
Palermo 1
Qingdao 1
Seattle 1
Shanghai 1
Singapore 1
São Paulo 1
Tallinn 1
Toronto 1
Zagreb 1
Zhengzhou 1
Totale 533
Nome #
Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. 96
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. 92
Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer 82
New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting 79
Prognostic relevance of PIK3CA mutations in breast cancer patients treated with primary dose-dense epirubicin/cyclophosphamide -> dose-dense docetaxel 65
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome 56
Allostatic Load as an Insight into the Psychological Burden after Primary Treatment in Women with Breast Cancer: Influence of Physical Side Effects and Pain Perception 51
Denosumab in breast cancer patients receiving aromatase inhibitors: A single-center observational study of effectiveness in adjuvant setting 48
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 46
Real-life use of denosumab 120 mg every 12 weeks in prolonged treatment over 2 years of patients with breast cancer bone metastases 45
Effectiveness of restoring vitamin B12 levels in the resolution of a case of erythema nodosum 41
Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management 37
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. 34
Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery 8
Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer 6
Totale 786
Categoria #
all - tutte 3.330
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.330


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202059 11 0 7 0 0 6 13 6 8 0 1 7
2020/2021100 1 7 3 9 13 3 14 4 14 5 18 9
2021/202282 3 0 17 5 0 1 0 3 3 10 6 34
2022/2023300 13 25 1 44 25 26 0 18 129 3 10 6
2023/2024112 7 3 2 2 6 21 1 8 0 3 17 42
2024/20255 5 0 0 0 0 0 0 0 0 0 0 0
Totale 786